Search results

Order by most recent / most popular / relevance

Results: 1-10 of 475

A look at the Myriad gene patent claims and the USPTO memo to examiners on Myriad

Foley & Lardner LLP
-
USA
-
June 17 2013

Now that the Supreme Court has issued its decision in the "ACLUMyriad" gene patents case (Association for Molecular Pathology v. Myriad Genetics

Maximizing the value of pre-AIA patent applications using first-to-file regime part I

Foley & Lardner LLP
-
USA
-
June 14 2013

The first-to-file provisions of the Leahy-Smith America Invents Act (AIA) took effect on March 16, 2013. The predominant view among patent

Supreme Court holds isolated naturally occurring DNA cannot be patented, sustains patent-eligibility of cDNA

Foley & Lardner LLP
-
USA
-
June 13 2013

While the Court's decision is not unexpected, it marks a significant change in the law, and reverses the decades-old USPTO practice of granting

US Patent Office issues guidance to examiners on Supreme Court’s Myriad decision

Foley & Lardner LLP
-
USA
-
June 13 2013

Today the USPTO issued guidance to Examiners on how to apply the Myriad Supreme Court decision to applications under examination. The guidance states

Monsanto avoids declaratory judgment action brought by organic farmers

Foley & Lardner LLP
-
USA
-
June 13 2013

In Organic Seed Growers and Trade Association v. Monsanto Co., the Federal Circuit dismissed the plaintiffs' declaratory judgment action against

Isolated DNA is not patent-eligible

Foley & Lardner LLP
-
USA
-
June 13 2013

Today the U.S. Supreme Court in Ass'n for Molecular Pathology v. Myriad Genetics, Inc., __ U.S. __ (2013), held that genes and DNA fragments merely

Supreme Court decides Myriad gene patents case, holds isolated human genes may not be patented

Foley & Lardner LLP
-
USA
-
June 13 2013

On June 13, 2013, the Supreme Court issued its long-awaited decision in the "ACLUMyriad" gene patents case (Association for Molecular Pathology v

Monsanto averts declaratory judgement suit

Foley & Lardner LLP
-
USA
-
June 13 2013

On June 10, 2013, the U.S. Court of Appeals for the Federal Circuit held that Monsanto's representation that it would not pursue farmers and seed

Supreme Court decides Myriad case: synthetic DNA held patentable & implications for nanotech

Foley & Lardner LLP
-
USA
-
June 13 2013

Today the Supreme Court rendered its decision in the landmark Myriad case, holding that naturally occurring DNA segments are not patentable, but

US patent “micro-entity” rules & other cost savings strategies: do you qualify for 75 off your us patent filing costs?

Foley & Lardner LLP
-
USA
-
June 12 2013

The short answer is that a company or individual who already is qualified as a small entity (which entitles you to 50 off US patent filing costs

next >

Search results

A look at the Myriad gene patent claims and the USPTO memo to examiners on Myriad

Maximizing the value of pre-AIA patent applications using first-to-file regime part I

Supreme Court holds isolated naturally occurring DNA cannot be patented, sustains patent-eligibility of cDNA

US Patent Office issues guidance to examiners on Supreme Court’s Myriad decision

Monsanto avoids declaratory judgment action brought by organic farmers

Isolated DNA is not patent-eligible

Supreme Court decides Myriad gene patents case, holds isolated human genes may not be patented

Monsanto averts declaratory judgement suit

Supreme Court decides Myriad case: synthetic DNA held patentable & implications for nanotech

US patent “micro-entity” rules & other cost savings strategies: do you qualify for 75 off your us patent filing costs?

Current Search

Suggested Facets

Author

Jurisdiction

Workarea